<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "8: enter into", fill: "#8db600"},
{source: "8: enter into", target: "8: transactions", fill: "#8db600"},
{source: "8: transactions", target: "8: difficulties", fill: "#8db600"},
{source: "8: difficulties", target: "8: integrating", fill: "#8db600"},
{source: "8: integrating", target: "8: products into", fill: "#8db600"},
{source: "8: products into", target: "8: key personnel from", fill: "#8db600"},
{source: "8: key personnel from", target: "8: businesses", fill: "#8db600"},
{source: "8: businesses", target: "8: regulatory approvals", fill: "#8db600"},
{source: "8: regulatory approvals", target: "8: higher costs", fill: "#8db600"},
{source: "8: higher costs", target: "8: integration than", fill: "#8db600"},
{source: "8: integration than", target: "8: significant financial", fill: "#8db600"},
{source: "8: significant financial", target: "8: managerial resources", fill: "#8db600"},
{source: "8: managerial resources", target: "8: would otherwise", fill: "#8db600"},
{source: "8: would otherwise", target: "8: development", fill: "#8db600"},
{source: "8: development", target: "8: operations", fill: "#8db600"},
{source: "8: enter into", target: "9: Consummating ", fill: "#e0ffff"},
{source: "9: Consummating ", target: "9: transactions could also", fill: "#e0ffff"},
{source: "9: transactions could also", target: "9: additional", fill: "#e0ffff"},
{source: "9: additional", target: "9: interest expense as well as unforeseen", fill: "#e0ffff"},
{source: "9: interest expense as well as unforeseen", target: "9: contingent liabilities", fill: "#e0ffff"},
{source: "9: contingent liabilities", target: "9: which could", fill: "#e0ffff"},
{source: "9: which could", target: "9: financial condition", fill: "#e0ffff"},
{source: "9: financial condition", target: "9: operations", fill: "#e0ffff"},
{source: "9: Consummating ", target: "11: significant amount", fill: "#9370db"},
{source: "11: significant amount", target: "11: operations outside", fill: "#9370db"},
{source: "11: operations outside", target: "11: United States ", fill: "#9370db"},
{source: "11: United States ", target: "11: which subjects us", fill: "#9370db"},
{source: "11: which subjects us", target: "11: additional", fill: "#9370db"},
{source: "11: additional", target: "11: profitability", fill: "#9370db"},
{source: "11: significant amount", target: "168: contribution", fill: "#e3256b"},
{source: "168: contribution", target: "168: distribution", fill: "#e3256b"},
{source: "168: distribution", target: "168: agreement", fill: "#e3256b"},
{source: "168: agreement", target: "168: each agreed", fill: "#e3256b"},
{source: "168: each agreed", target: "168: indemnify each", fill: "#e3256b"},
{source: "168: indemnify each", target: "168: spinoff with respect", fill: "#e3256b"},
{source: "168: spinoff with respect", target: "168: debt liabilities", fill: "#e3256b"},
{source: "168: debt liabilities", target: "168: obligations", fill: "#e3256b"},
{source: "168: obligations", target: "168: respective companies", fill: "#e3256b"},
{source: "168: contribution", target: "START_HERE", fill: "#e3256b"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Environmental Services</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Policy</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Travel to meet</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Promise policy support</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Bombings</td>
    </tr>
    <tr>
      <td>Covert monitoring</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_figures">Significant figures</a></td>
      <td>Significant figures (also known as the significant digits, precision or resolution) of a number in positional notation are digits in the number that are reliable and necessary to indicate the quantity of something.\nIf a number expressing the result of a measurement (e.g., length, pressure, volume, or mass) has more digits than the number of digits allowed by the measurement resolution, then only as many digits as allowed by the measurement resolution are reliable, and so only these can be significant figures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Met_Operations">Met Operations</a></td>
      <td>Met Operations, also known as Met Ops, is one of the four business groups which forms the Metropolitan Police Service. It was created during the 2018-19 restructuring of the service, amalgamating many of its functions from the Operations side of the Specialist Crime &amp; Operations Directorate formed in 2012, with the Specialist Crime side of that Directorate placed under the new Frontline Policing Directorate.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Balance_sheet">Balance sheet</a></td>
      <td>In financial accounting, a balance sheet (also known as statement of financial position or statement of financial condition) is a summary of the financial balances of an individual or organization, whether it be a sole proprietorship, a business partnership, a corporation, private limited company or other organization such as government or not-for-profit entity. Assets, liabilities and ownership equity are listed as of a specific date, such as the end of its financial year.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_law">Financial law</a></td>
      <td>Financial law is the law and regulation of the insurance, derivatives, commercial banking, capital markets and investment management sectors. Understanding Financial law is crucial to appreciating the creation and formation of banking and financial regulation, as well as the legal framework for finance generally.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_analysis">Financial analysis</a></td>
      <td>Financial analysis (also referred to as financial statement analysis or accounting analysis or Analysis of finance) refers to an assessment of the viability, stability, and profitability of a business, sub-business or project. \nIt is performed by professionals who prepare reports using ratios and other techniques, that make use of information taken from financial statements and other reports.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Form_10-K">Form 10-K</a></td>
      <td>A Form 10-K is an annual report required by the U.S. Securities and Exchange Commission (SEC), that gives a comprehensive summary of a company's financial performance. Although similarly named, the annual report on Form 10-K is distinct from the often glossy "annual report to shareholders," which a company must send to its shareholders when it holds an annual meeting to elect directors (though some companies combine the annual report and the 10-K into one document).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Krishna_Raja_Sagara">Krishna Raja Sagara</a></td>
      <td>Krishna Raja Sagara, also popularly known as KRS, is a lake and the dam that creates it. They are close to the settlement of Krishna Raja Sagara in the Indian State of Karnataka.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States">United States</a></td>
      <td>The United States of America is a federal republic consisting of 50 states, a federal district (Washington, D.C., the capital city of the United States), five major territories, and various minor islands. The 48 contiguous states and Washington, D.C., are in North America between Canada and Mexico.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/President_of_the_United_States">President of the United States</a></td>
      <td>The president of the United States (POTUS) is the head of state and head of government of the United States of America. The president directs the executive branch of the federal government and is the commander-in-chief of the United States Armed Forces.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Navy">United States Navy</a></td>
      <td>The United States Navy (USN) is the maritime service branch of the United States Armed Forces and one of the eight uniformed services of the United States. It is the largest and most powerful navy in the world, with the estimated tonnage of its active battle fleet alone exceeding the next 13 navies combined, including 11 U.S. allies or partner nations as of 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Marine_Corps">United States Marine Corps</a></td>
      <td>The United States Marine Corps (USMC), also referred to as the United States Marines, is the maritime land force service branch of the United States Armed Forces responsible for conducting expeditionary and amphibious operations through combined arms, implementing its own infantry, artillery, aerial, and special operations forces. The U.S. Marine Corps is one of the eight uniformed services of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Congress">United States Congress</a></td>
      <td>The United States Congress is the legislature of the federal government of the United States. It is bicameral, being composed of a lower body, the House of Representatives, and an upper body, the Senate.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/History_of_the_United_States">History of the United States</a></td>
      <td>The history of the lands that became the United States began with the arrival of the first people in the Americas around 15,000 BC. Numerous indigenous cultures formed, and many saw transformations in the 16th century away from more densely populated lifestyles and towards reorganized polities elsewhere.  The European colonization of the Americas began in the late 15th century, however most colonies in what would later become the United States were settled after 1600.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_presidents_of_the_United_States">List of presidents of the United States</a></td>
      <td>The president of the United States is the head of state and head of government of the United States, indirectly elected to a four-year term by the American people through the Electoral College. The office holder leads the executive branch of the federal government and is the commander-in-chief of the United States Armed Forces.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Profit_(economics)">Profit (economics)</a></td>
      <td>An economic profit is the difference between the revenue a  commercial entity has received from its outputs and the opportunity costs of its inputs. It equals to total revenue minus total cost, including both explicit and implicit costs.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Profitability_analysis">Profitability analysis</a></td>
      <td>In cost accounting, profitability analysis is an analysis of the profitability of an organisation's output. Output of an organisation can be grouped into products, customers, locations, channels and/or transactions.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Profitability_index">Profitability index</a></td>
      <td>Profitability index (PI), also known as profit investment ratio (PIR) and value investment ratio (VIR), is the ratio of payoff to investment of a proposed project. It is a useful tool for ranking projects because it allows you to quantify the amount of value created per unit of investment.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Customer_Profitability_Analysis">Customer Profitability Analysis</a></td>
      <td>Customer Profitability Analysis (in short CPA) is a management accounting and a credit underwriting method, allowing businesses and lenders to determine the profitability of each customer or segments of customers, by attributing profits and costs to each customer separately. CPA can be applied at the individual customer level (more time consuming, but providing a better understanding of business situation) or at the level of customer aggregates / groups (e.g.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Profitable_growth">Profitable growth</a></td>
      <td>Profitable Growth is the combination of profitability and growth, more precisely the combination of Economic Profitability and Growth of Free cash flows. Profitable growth is aimed at seducing the financial community; it emerged in the early 80s when shareholder value creation became firms’ main objective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Customer_profitability">Customer profitability</a></td>
      <td>Customer Profitability Analysis (in short CPA) is a management accounting and a credit underwriting method, allowing businesses and lenders to determine the profitability of each customer or segments of customers, by attributing profits and costs to each customer separately. CPA can be applied at the individual customer level (more time consuming, but providing a better understanding of business situation) or at the level of customer aggregates / groups (e.g.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/SAP_ERP">SAP ERP</a></td>
      <td>SAP ERP is an enterprise resource planning software developed by the German company SAP SE. SAP ERP incorporates the key business functions of an organization. The latest version of SAP ERP (V.6.0) was made available in 2006.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Porter's_five_forces_analysis">Porter's five forces analysis</a></td>
      <td>Porter's Five Forces Framework is a method of analysing the operating environment of a competition of a business. It draws from industrial organization (IO) economics to derive five forces that determine the competitive intensity and, therefore, the attractiveness (or lack thereof) of an industry in terms of its profitability.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collateralized_debt_obligation">Collateralized debt obligation</a></td>
      <td>A collateralized debt obligation (CDO) is a type of structured asset-backed security (ABS). Originally developed as instruments for the corporate debt markets, after 2002 CDOs became vehicles for refinancing mortgage-backed securities (MBS).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Solidary_obligations">Solidary obligations</a></td>
      <td>A solidary obligation, or an obligation in solidum, is a type of obligation in the civil law jurisprudence that allows either obligors to be bound together, each liable for the whole performance, or obligees to be bound together, all owed just a single performance and each entitled to the entirety of it.  In general, solidarity of an obligation is never presumed, and it must be expressly stated as the true intent of the parties' will.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Law_of_obligations">Law of obligations</a></td>
      <td>The law of obligations is one branch of private law under the civil law legal system and so-called "mixed" legal systems. It is the body of rules that organizes and regulates the rights and duties arising between individuals.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Contract">Contract</a></td>
      <td>A contract is a legally enforceable agreement that creates, defines, and governs mutual rights and obligations among its parties. A contract typically involves the transfer of goods, services, money, or a promise to transfer any of those at a future date.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Deontology">Deontology</a></td>
      <td>In moral philosophy, deontological ethics or deontology (from Greek: δέον, 'obligation, duty' + λόγος, 'study') is the normative ethical theory that the morality of an action should be based on whether that action itself is right or wrong under a series of rules, rather than based on the consequences of the action. It is sometimes described as duty-, obligation-, or rule-based ethics.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Nondelegable_obligation">Nondelegable obligation</a></td>
      <td>A nondelegable obligation (also known as a non-delegable duty) is a legal obligation or duty which cannot legally be delegated or, if delegated, the principal is still liable for said obligation.  They are also known as non-assignable duties or obligations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collateralized_loan_obligation">Collateralized loan obligation</a></td>
      <td>Collateralized loan obligations (CLOs) are a form of securitization where payments from multiple middle sized and large business loans are pooled together and passed on to different classes of owners in various tranches. A CLO is a type of collateralized debt obligation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Unilateral_gratuitous_obligations">Unilateral gratuitous obligations</a></td>
      <td>Unilateral gratuitous obligations (also known as unilateral voluntary obligations or gratuitous promises) are obligations undertaken voluntarily, when a person promises in definite terms to do something to benefit or favour another, and may therefore be under a legal obligation to keep their promise.\nAn example would be a promise to donate a sum of money to a charity.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>ADVANCED MEDICAL OPTICS INC      Item 1A Risk Factors         You <font color="blue">should carefully</font> consider the <font color="blue">following risks</font> and other information</td>
    </tr>
    <tr>
      <td>These risks and <font color="blue">uncertainties</font> are not the only ones we face</td>
    </tr>
    <tr>
      <td>Others that we     do not know about now, or that we do not now think are important, may also     impair our business</td>
    </tr>
    <tr>
      <td>The <font color="blue">risks described</font> in this section could cause our     actual results to <font color="blue">differ <font color="blue">materially</font> from</font> those anticipated</td>
    </tr>
    <tr>
      <td>Risks Relating to Our Business         We  may  not <font color="blue">successfully</font> make or <font color="blue">integrate <font color="blue">acquisition</font>s</font> or <font color="blue">enter into</font>     <font color="blue">strategic alliances</font></td>
    </tr>
    <tr>
      <td>As part of our business strategy, we intend to <font color="blue">pursue selected <font color="blue">acquisition</font>s</font>     and <font color="blue">strategic alliances</font> and <font color="blue">partnerships</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">compete with</font> other ophthalmic     surgical  products  and  eye  care  companies, among others, for these     <font color="blue">opportunities</font>  and we <font color="blue">cannot assure</font> you that we will be able to effect     <font color="blue">strategic alliances</font>, <font color="blue">partnerships</font> or <font color="blue"><font color="blue">acquisition</font>s on <font color="blue">commercially</font> reasonable</font>     terms  or  at all</td>
    </tr>
    <tr>
      <td>Even if we do <font color="blue">enter into</font> these <font color="blue">transactions</font>, we may     experience:         •                  delays in realizing the benefits we anticipate, or we may     not realize the benefits we anticipate at all;         •                  <font color="blue"><font color="blue">difficult</font>ies</font> in <font color="blue">integrating</font> any acquired companies and     <font color="blue">products into</font> our existing business;         •                  attrition of <font color="blue">key <font color="blue">personnel from</font></font> acquired <font color="blue">businesses</font>;         •                  costs or charges;         •                  <font color="blue"><font color="blue">difficult</font>ies</font> or delays in obtaining <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font>;         •                  <font color="blue">higher costs</font> of <font color="blue">integration than</font> we anticipated; or         •                   unforeseen  operating  <font color="blue"><font color="blue">difficult</font>ies</font>  that  require     <font color="blue"><font color="blue">significant</font> financial</font> and <font color="blue">managerial resources</font> that <font color="blue">would otherwise</font> be     available  for  the  ongoing  <font color="blue">development</font> or expansion of our existing     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Consummating </font>these <font color="blue">transactions</font> could also result in the incurrence of     <font color="blue">additional</font>  debt  and  related interest expense, as well as unforeseen     <font color="blue">contingent <font color="blue">liabilities</font></font>, all of <font color="blue">which could</font> have a material adverse effect on     our business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We may also     issue <font color="blue">additional</font> equity in <font color="blue">connection with</font> these <font color="blue">transactions</font>, which would     dilute our <font color="blue">existing <font color="blue">stockholders</font></font></td>
    </tr>
    <tr>
      <td>14     ______________________________________________________________________         We conduct a <font color="blue"><font color="blue">significant</font> amount</font> of our sales and <font color="blue">operations</font> outside of the     <font color="blue">United States</font>, <font color="blue">which subjects us</font> to <font color="blue">additional</font> business risks that may cause     our <font color="blue">profitability</font> to decline</td>
    </tr>
    <tr>
      <td>Because we <font color="blue">manufacture</font> and sell a <font color="blue">significant</font> portion of our products in a     number of <font color="blue">foreign countries</font>, our business is subject to <font color="blue">risks associated</font>     with doing business <font color="blue"><font color="blue">international</font>ly</font></td>
    </tr>
    <tr>
      <td>In particular, our products are sold in     over 60 countries, and our <font color="blue"><font color="blue">manufacturing</font> <font color="blue">facilities</font></font> are <font color="blue">located outside</font> the     <font color="blue">continental</font>  <font color="blue">United States</font>, in Anasco, Puerto Rico; Madrid, Spain; and     Hangzhou, China</td>
    </tr>
    <tr>
      <td>In <font color="blue">connection with</font> the <font color="blue">acquisition</font> of Pfizer’s ophthalmic     surgical business, we acquired Pfizer’s <font color="blue"><font color="blue">ophthalmic surgical</font> products</font> and     <font color="blue">certain <font color="blue">manufacturing</font></font> and research and <font color="blue">development</font> <font color="blue">facilities</font> located in     Uppsala, Sweden and Groningen, Netherlands</td>
    </tr>
    <tr>
      <td>In 2005, on an <font color="blue">historical basis</font>,     we derived approximately dlra618dtta2 million, or 67prca, of our net sales, from     sales of our <font color="blue">products outside</font> of the <font color="blue">United States</font>, including 19prca of our net     sales in Japan</td>
    </tr>
    <tr>
      <td>We intend to continue to pursue growth <font color="blue">opportunities</font> in     sales <font color="blue"><font color="blue">international</font>ly</font>, <font color="blue">which could</font> expose us to greater <font color="blue">risks associated</font>     <font color="blue">with <font color="blue"><font color="blue">international</font> sales</font></font> and <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">international</font> <font color="blue">operations</font> are,     and <font color="blue">will continue</font> to be, subject to a number of risks and <font color="blue">potential costs</font>,     including:         •                  unexpected changes in <font color="blue">foreign <font color="blue">regulatory</font> <font color="blue">requirements</font></font>;         •                   differing  local  product  <font color="blue">preferences</font> and product     <font color="blue">requirements</font>;         •                  <font color="blue">fluctuations</font> in <font color="blue">foreign currency <font color="blue">exchange rates</font></font>;         •                  political and <font color="blue">economic instability</font>;         •                  changes in <font color="blue">foreign medical reimbursement</font> and coverage     policies and programs;         •                  <font color="blue">diminished protection</font> of <font color="blue"><font color="blue">intellectual</font> property</font> in some     <font color="blue">countries outside</font> of the <font color="blue">United States</font>;         •                  <font color="blue">trade protection measures</font> and import or <font color="blue">export licensing</font>     <font color="blue">requirements</font>;         •                  <font color="blue"><font color="blue">difficult</font>y</font> in staffing and managing foreign <font color="blue">operations</font>;         •                  <font color="blue">differing labor <font color="blue">regulations</font></font>; and         •                  <font color="blue">potentially negative <font color="blue">consequences</font> from</font> changes in tax     laws</td>
    </tr>
    <tr>
      <td>Any  of these factors may, <font color="blue">individually</font> or as a group, have a material     adverse effect on our business and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In addition, we     are <font color="blue">particularly susceptible</font> to the occurrence of any of these risks in     Japan, due to our <font color="blue">high concentration</font> of sales in Japan</td>
    </tr>
    <tr>
      <td>As we expand our existing <font color="blue">international</font> <font color="blue">operations</font>, we <font color="blue">may encounter new</font>     risks</td>
    </tr>
    <tr>
      <td>For example, as we <font color="blue">focus on building</font> our <font color="blue"><font color="blue">international</font> sales</font> and     <font color="blue"><font color="blue">distribution</font> networks</font> in <font color="blue">new <font color="blue">geographic regions</font></font>, we <font color="blue">must continue</font> to develop     <font color="blue"><font color="blue">relationships</font> with qualified local distributors</font> and <font color="blue">trading companies</font></td>
    </tr>
    <tr>
      <td>If we     are not successful in developing these <font color="blue">relationships</font>, we may not be able to     grow sales in these <font color="blue">geographic regions</font></td>
    </tr>
    <tr>
      <td>These or other similar <font color="blue">risks could</font>     <font color="blue"><font color="blue">adversely</font> affect</font> our revenue and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We are exposed to <font color="blue">foreign currency risks from</font> our <font color="blue">international</font> <font color="blue">operations</font>     that could <font color="blue"><font color="blue">adversely</font> affect</font> our financial results</td>
    </tr>
    <tr>
      <td>A <font color="blue">significant</font> portion of our sales and operating costs are, and from time to     time,  a  portion  of  our <font color="blue"><font color="blue">indebtedness</font> may</font> be, <font color="blue">denominated</font> in foreign     currencies</td>
    </tr>
    <tr>
      <td>We are therefore exposed to <font color="blue">fluctuations</font> in the <font color="blue">exchange rates</font>     between the US dollar and the currencies in which our foreign <font color="blue">operations</font>     receive revenues and <font color="blue">pay expenses</font>, including <font color="blue">debt service</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">consolidated</font>     financial results are <font color="blue">denominated</font> in US dollars and therefore, during     times of a <font color="blue">strengthening</font> US dollar, our reported <font color="blue"><font color="blue">international</font> sales</font> and     <font color="blue">earnings will</font> be reduced because the <font color="blue">local currency will translate into</font>     fewer US dollars</td>
    </tr>
    <tr>
      <td>In addition, the assets and <font color="blue">liabilities</font> of our non-US     <font color="blue">subsidiaries</font> are <font color="blue">translated into</font> US <font color="blue">dollars at</font> the <font color="blue">exchange rates</font> in     effect at the <font color="blue">balance sheet date</font></td>
    </tr>
    <tr>
      <td>Revenues and expenses are <font color="blue">translated into</font>     US  dollars  at  the  <font color="blue">weighted average exchange rate</font> for the period</td>
    </tr>
    <tr>
      <td><font color="blue">Translation </font><font color="blue">adjustments</font> arising from the use of differing <font color="blue">exchange rates</font>     from period to period are included in “<font color="blue">Accumulated </font>other <font color="blue">comprehensive</font>     income (loss)” in “Stockholders’ equity</td>
    </tr>
    <tr>
      <td>” Gains and losses resulting from     foreign  currency  <font color="blue">fluctuations</font> and <font color="blue">remeasurements</font> relating to foreign     <font color="blue">operations</font> deemed to be operating in US <font color="blue">dollar functional currency</font> are     included in “Other, net” in our <font color="blue">consolidated</font> statements of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Accordingly, changes in currency <font color="blue">exchange rates</font> will cause our <font color="blue">net earnings</font>     and <font color="blue">stockholders</font>’ equity to fluctuate</td>
    </tr>
    <tr>
      <td>15     ______________________________________________________________________         If we do not <font color="blue">introduce new <font color="blue">commercially</font> successful products</font> in a timely     manner, our <font color="blue"><font color="blue">products may</font> become obsolete over</font> time, <font color="blue">customers may</font> not buy     our products and our revenue and <font color="blue">profitability</font> may decline</td>
    </tr>
    <tr>
      <td>Demand for our <font color="blue">products may</font> change in ways we may not anticipate because of:         •                  evolving customer needs;         •                  the <font color="blue">introduction</font> of <font color="blue">new products</font> and <font color="blue">technologies</font>;         •                  evolving surgical practices; and         •                  evolving industry standards</td>
    </tr>
    <tr>
      <td>Without the timely <font color="blue">introduction</font> of new <font color="blue">commercially</font> successful products and     <font color="blue">enhancements</font>, our <font color="blue"><font color="blue">products may</font> become obsolete over</font> time, in which case our     sales and operating results would suffer</td>
    </tr>
    <tr>
      <td>The success of our new product     <font color="blue">offerings will depend on several factors</font>, including our ability to:         •                  properly identify and anticipate customer needs;         •                  <font color="blue">commercialize <font color="blue">new products</font></font> in a cost-<font color="blue">effective</font> and timely     manner;         •                  <font color="blue">manufacture</font> and deliver products in <font color="blue">sufficient volumes on</font>     time;         •                  obtain <font color="blue"><font color="blue">regulatory</font> approval</font> for such <font color="blue">new products</font>;         •                  <font color="blue">different</font>iate our offerings from <font color="blue">competitors</font>’ offerings;         •                  achieve positive <font color="blue">clinical outcomes</font>;         •                  satisfy the <font color="blue">increased demands by health care payors</font>,     providers and patients for lower-cost procedures;         •                  innovate and develop new materials, product designs and     <font color="blue">surgical techniques</font>; and         •                   provide adequate medical and/or consumer education     relating to <font color="blue">new products</font> and <font color="blue">attract key surgeons</font> to advocate these new     products</td>
    </tr>
    <tr>
      <td>Moreover, <font color="blue">innovations</font> <font color="blue">generally</font> will require a substantial <font color="blue">investment</font> in     research and <font color="blue">development</font> before we can determine the <font color="blue">commercial viability</font> of     these <font color="blue">innovations</font> and we may not have the <font color="blue">financial resources necessary</font> to     fund these <font color="blue">innovations</font></td>
    </tr>
    <tr>
      <td>In addition, even if we are able to <font color="blue">successfully</font>     develop <font color="blue">enhancements</font> or <font color="blue">new generations</font> of our products, these <font color="blue">enhancements</font>     or <font color="blue">new generations</font> of <font color="blue">products may</font> not produce revenue in excess of the     costs of <font color="blue">development</font> and they may be quickly rendered <font color="blue">obsolete by</font> changing     customer <font color="blue">preferences</font> or the <font color="blue">introduction</font> by our <font color="blue">competitors</font> of products     embodying new <font color="blue">technologies</font> or features</td>
    </tr>
    <tr>
      <td>We are <font color="blue">implementing</font> a <font color="blue">product <font color="blue">rationalization</font></font> and <font color="blue">repositioning</font> plan, which     will require <font color="blue"><font color="blue">significant</font> financial</font> and <font color="blue">personnel resources</font> and may not be     successful</td>
    </tr>
    <tr>
      <td>On  October  31,  2005,  our  Board  of  <font color="blue">Directors  </font>approved a product     <font color="blue">rationalization</font> and <font color="blue">repositioning</font> plan covering the <font color="blue">discontinuation</font> of     non-strategic cataract surgical and <font color="blue">eye <font color="blue">care products</font></font> and the <font color="blue">elimination</font> or     <font color="blue">redeployment</font>  of  resources that support these <font color="blue">product lines</font></td>
    </tr>
    <tr>
      <td>The plan     includes  <font color="blue">organization</font>al  changes and <font color="blue">potential <font color="blue">reductions</font></font> in force in     <font color="blue">manufacturing</font>, sales and <font color="blue">marketing <font color="blue">associated with</font></font> these <font color="blue">product lines</font>, as     well  as  <font color="blue">organization</font>al changes in research and <font color="blue">development</font> and other     <font color="blue">corporate functions designed</font> to align the <font color="blue">organization</font> with our strategy and     strategic business unit <font color="blue">organization</font></td>
    </tr>
    <tr>
      <td>The plan <font color="blue">further calls</font> for increasing     our <font color="blue">investment</font> in key growth <font color="blue">opportunities</font>, specifically our refractive     <font color="blue">implant product line</font> and <font color="blue"><font color="blue">international</font> laser vision <font color="blue">correction</font></font> business, and     <font color="blue">accelerating</font> the <font color="blue">implementation</font> of <font color="blue">productivity initiatives</font></td>
    </tr>
    <tr>
      <td>We  expect  that  <font color="blue">implementation</font>  of  the  <font color="blue">product <font color="blue">rationalization</font></font> and     <font color="blue">repositioning</font> plan will result in <font color="blue">significant</font> pre-tax charges, a substantial     portion of which are expected to be <font color="blue">cash <font color="blue">expenditures</font></font></td>
    </tr>
    <tr>
      <td>In addition, because     we are in the <font color="blue">preliminary stages</font> of <font color="blue">effectuating</font> the plan and are subject to     laws and <font color="blue">regulations</font> of <font color="blue">several foreign jurisdictions</font> that will require     <font color="blue">consultations</font> and <font color="blue">negotiations with</font> works councils, labor <font color="blue">organization</font>s and     <font color="blue">local <font color="blue">authorities</font></font> the effects of which we can not <font color="blue">yet fully evaluate</font>, the     <font color="blue">final costs</font> of the plan may vary <font color="blue">significant</font>ly from our initial estimates</td>
    </tr>
    <tr>
      <td><font color="blue">Implementation </font>of the plan also will require substantial                                           16     ______________________________________________________________________         <font color="blue">personnel resources</font> and may result in diversion of <font color="blue">management</font>’s attention     away  from  other  business <font color="blue">activities</font> that could be <font color="blue">beneficial</font> to our     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue">successfully</font> execute the plan as, and in     the  time  frame, anticipated</td>
    </tr>
    <tr>
      <td>In addition, lost sales of <font color="blue">discontinued</font>     products  may not be <font color="blue"><font color="blue">sufficiently</font> offset by sales from promoted</font> or new     products, <font color="blue">which could</font> decrease our revenues, margins, profits and cash     flows</td>
    </tr>
    <tr>
      <td>We <font color="blue">rely on certain suppliers</font> and <font color="blue">manufacture</font>rs for <font color="blue">raw materials</font> and other     products and are vulnerable to <font color="blue">fluctuations</font> in the <font color="blue">availability</font> and price of     <font color="blue">such products</font> and services</td>
    </tr>
    <tr>
      <td>We  purchase certain <font color="blue">raw materials</font> and other products from third-party     suppliers and vendors, sometimes from limited sources</td>
    </tr>
    <tr>
      <td>Our suppliers and     <font color="blue">vendors may</font> not provide the <font color="blue">raw materials</font> or other products needed by us in     the <font color="blue">quantities requested</font>, in a <font color="blue">timely manner</font>, or at a price we are willing     to pay</td>
    </tr>
    <tr>
      <td>In the event any of our third-party suppliers or vendors were to     become unable or unwilling to continue to provide important <font color="blue">raw materials</font>     and third-party products in the required volumes and <font color="blue">quality levels</font> or in a     timely  manner, we would be required to identify and obtain acceptable     <font color="blue">replacement</font>  supply  sources</td>
    </tr>
    <tr>
      <td>We may not be able to obtain <font color="blue">alternative</font>     suppliers and <font color="blue">vendors on</font> a <font color="blue">timely basis</font>, or at all, <font color="blue">which could</font> result in     lost sales because of our <font color="blue">inability</font> to <font color="blue">manufacture</font> products containing such     raw  materials  or deliver products we <font color="blue">sell from certain suppliers</font></td>
    </tr>
    <tr>
      <td>In     addition, we also rely on certain <font color="blue">manufacture</font>rs for some of our products</td>
    </tr>
    <tr>
      <td>We     have <font color="blue">historically outsourced</font> the <font color="blue">manufacture</font> of our <font color="blue">phacoemulsification</font>     equipment to <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>If we were unable to renew our third-party     <font color="blue">manufacturing</font>  <font color="blue"><font color="blue">agreement</font>s</font>,  or  if  the  <font color="blue">manufacture</font>rs  were  to cease     <font color="blue">manufacturing</font> any of these products for us for any reason, we may not be     able to find <font color="blue">alternative</font> <font color="blue">manufacture</font>rs on terms favorable to us, in a timely     manner,  or at all</td>
    </tr>
    <tr>
      <td>If any of these <font color="blue">events should</font> occur, our business,     <font color="blue">financial condition</font> and results of <font color="blue">operations</font> could be <font color="blue"><font color="blue">materially</font> <font color="blue">adversely</font></font>     affected</td>
    </tr>
    <tr>
      <td>We <font color="blue">face intense <font color="blue">competition</font></font>, and our failure to <font color="blue"><font color="blue">compete <font color="blue"><font color="blue">effective</font>ly</font></font> could</font>     have  a  material  adverse  effect on our <font color="blue">profitability</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">face intense <font color="blue">competition</font></font> in the markets for our <font color="blue">ophthalmic surgical</font> and     <font color="blue">eye <font color="blue">care products</font></font> and these markets are subject to rapid and <font color="blue">significant</font>     <font color="blue">technological</font> change</td>
    </tr>
    <tr>
      <td>We have numerous <font color="blue">competitors</font> in the <font color="blue"><font color="blue">United States</font> </font>and     abroad, including, among others, large companies such as Alcon, Inc, a     publicly  traded subsidiary of Nestle SA; Bausch &amp; Lomb; CIBA Vision     Corporation, a unit of Novartis; Moria; Intralase; Eyeonics; Hoya, Santen,     Corneal, CooperVision; and Vistakon, a Johnson and Johnson company</td>
    </tr>
    <tr>
      <td>Many of     our <font color="blue">competitors</font> have <font color="blue">substantially</font> more resources and a <font color="blue">greater marketing</font>     scale  than we do</td>
    </tr>
    <tr>
      <td>We may not be able to sustain our <font color="blue">current levels</font> of     <font color="blue">profitability</font>  and  <font color="blue">growth as <font color="blue">competitive</font> pressures</font>, including pricing     pressure  from <font color="blue">competitors</font>, increase</td>
    </tr>
    <tr>
      <td>In addition, if we are unable to     develop and produce or market our products to <font color="blue"><font color="blue"><font color="blue">effective</font>ly</font> <font color="blue">compete against</font></font>     our <font color="blue">competitors</font>, our operating results <font color="blue">will <font color="blue">materially</font> suffer</font></td>
    </tr>
    <tr>
      <td>We also     <font color="blue">compete against</font> a large number of providers of <font color="blue">alternative</font> vision <font color="blue">correction</font>     solutions, some of which may have <font color="blue">greater financial resources than us</font></td>
    </tr>
    <tr>
      <td>New     or <font color="blue">different</font> methods of vision <font color="blue">correction</font> are <font color="blue">continually</font> being introduced</td>
    </tr>
    <tr>
      <td>Any of these <font color="blue">competitive</font> pressures could result in decreased demand for our     products</td>
    </tr>
    <tr>
      <td><font color="blue">Because  </font>of our leading market position in the laser vision <font color="blue">correction</font>     business, all of our <font color="blue">competitors</font> target our market share in order to grow     their  own  revenues</td>
    </tr>
    <tr>
      <td>We can <font color="blue">give no assurance</font> that we will be able to     maintain or grow our <font color="blue">existing market</font> share and it may, in fact, be required     to incur considerable <font color="blue">expenditures</font> in order to maintain or increase that     market share</td>
    </tr>
    <tr>
      <td>Should our <font color="blue">procedure market</font> share decline, it could have a     material adverse effect on our business, <font color="blue">financial position</font>, and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Trends in the <font color="blue"><font color="blue">contact lens care market</font> may negatively impact</font> our eye care     business</td>
    </tr>
    <tr>
      <td>Our eye care business is <font color="blue">impacted by trends</font> in the <font color="blue">contact lens care market</font>     such as more <font color="blue">simplified disinfection systems</font> and <font color="blue">technological</font> and medical     advances in <font color="blue">surgical techniques</font> for the <font color="blue">correction</font> of <font color="blue">vision impairment</font></td>
    </tr>
    <tr>
      <td>Less  expensive  one-bottle  <font color="blue">chemical disinfection systems</font> have gained     <font color="blue">popularity among soft contact lens wearers instead</font> of peroxide-based lens     <font color="blue">care products</font></td>
    </tr>
    <tr>
      <td>Also, the growing use and <font color="blue">acceptance</font> of daily and extended     wear contact lenses and laser <font color="blue">correction</font> procedures, along with the other     factors above, could have the effect of continuing to <font color="blue">reduce demand</font> for lens     care  products  <font color="blue">generally</font></td>
    </tr>
    <tr>
      <td>Our  marketing  and sales plans may not be     <font color="blue">appropriate</font> or sufficient to mitigate the effect of these trends on our eye     care business and, as a result, our eye care business may suffer</td>
    </tr>
    <tr>
      <td>If we are unable to protect our <font color="blue"><font color="blue">intellectual</font> property</font> rights, our business     and <font color="blue">prospects may</font> be harmed</td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">compete <font color="blue"><font color="blue">effective</font>ly</font></font> is <font color="blue">dependent upon</font> our ability to protect     and preserve the <font color="blue"><font color="blue">proprietary</font> aspects</font> of the designs, processes, <font color="blue">technologies</font>     and materials owned by, used by or licensed to us</td>
    </tr>
    <tr>
      <td>We have numerous US     patents and <font color="blue">corresponding foreign patents</font> that are expected to expire by     their own <font color="blue">terms at various dates</font> and have <font color="blue">additional</font> patent <font color="blue">applications</font>     pending that may not result in <font color="blue">issued patents</font></td>
    </tr>
    <tr>
      <td>Our failure to secure these     <font color="blue">patents may limit</font> our ability to protect the <font color="blue"><font color="blue">intellectual</font> property</font> rights     that these <font color="blue">applications</font> were intended to cover</td>
    </tr>
    <tr>
      <td>Although we have attempted     to protect our <font color="blue">proprietary</font> property, <font color="blue">technologies</font> and <font color="blue">processes both</font> in the     <font color="blue"><font color="blue">United States</font> </font>and in <font color="blue">foreign countries</font> through a <font color="blue">combination</font> of <font color="blue">patent law</font>,     trade                                           17     ______________________________________________________________________         secrets  and  non-disclosure  <font color="blue"><font color="blue">agreement</font>s</font>,  these  may be insufficient</td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>may be able to <font color="blue">design around</font> our patents to <font color="blue">compete <font color="blue"><font color="blue">effective</font>ly</font></font>     with our products</td>
    </tr>
    <tr>
      <td>We also may not be able to prevent <font color="blue">third parties</font> from     using our <font color="blue">technology</font> without our authorization, breaching any non-disclosure     <font color="blue"><font color="blue">agreement</font>s</font> with us, or <font color="blue">independently</font> developing <font color="blue">technology</font> that is similar     to ours</td>
    </tr>
    <tr>
      <td>The use of our <font color="blue">technology</font> or similar <font color="blue">technology</font> by others could     reduce or eliminate any <font color="blue">competitive</font> advantage we have developed, cause us to     lose sales or <font color="blue">otherwise harm</font> our business</td>
    </tr>
    <tr>
      <td>If it became necessary for us to     resort to <font color="blue">litigation</font> to protect these rights, any <font color="blue">proceedings could</font> be     costly and we may not prevail</td>
    </tr>
    <tr>
      <td>Further, we may not be able to obtain patents     or other <font color="blue">protections on</font> our future <font color="blue">innovations</font></td>
    </tr>
    <tr>
      <td>In addition, because of the     <font color="blue">differences</font> in foreign patent and other <font color="blue">laws <font color="blue">concerning</font> <font color="blue"><font color="blue">proprietary</font> rights</font></font>,     our  <font color="blue">products may</font> not receive the same degree of protection in foreign     <font color="blue">countries as</font> they would in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that:         •                   pending  patent <font color="blue">applications</font> will result in issued     patents;         •                   patents  issued  to  or <font color="blue">licensed by us will</font> not be     challenged by <font color="blue">third parties</font>; or         •                  our <font color="blue">patents will</font> be found to be valid or <font color="blue">sufficiently</font>     broad to protect our <font color="blue">technology</font> or <font color="blue">provide us with</font> a <font color="blue">competitive</font> advantage</td>
    </tr>
    <tr>
      <td>We may be subject to <font color="blue"><font color="blue">intellectual</font> property</font> <font color="blue">litigation</font> and <font color="blue">infringement</font>     claims, <font color="blue">which could</font> cause us to incur <font color="blue">significant</font> expenses or <font color="blue">prevent us</font>     <font color="blue">from selling</font> our products</td>
    </tr>
    <tr>
      <td>There  is  a  substantial  amount  of <font color="blue">litigation</font> over patent and other     <font color="blue"><font color="blue">intellectual</font> property</font> rights in the <font color="blue">eye care industry</font> and in the ophthalmic     <font color="blue">surgical products</font> and <font color="blue">contact lens care market</font>s particularly</td>
    </tr>
    <tr>
      <td>The fact that     we have patents issued to us for our products does not mean that we will     always be able to <font color="blue">successfully</font> defend our patents and <font color="blue"><font color="blue">proprietary</font> rights</font>     against  <font color="blue">challenges</font>  or  claims  of <font color="blue">infringement</font> by our <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>A     successful claim of patent or other <font color="blue"><font color="blue">intellectual</font> property</font> <font color="blue">infringement</font> or     <font color="blue">misappropriation</font>  against  us  could  <font color="blue">adversely</font>  affect our growth and     <font color="blue">profitability</font>, in some <font color="blue">cases <font color="blue">materially</font></font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that our     products do not and will not infringe <font color="blue">issued patents</font> or other <font color="blue">intellectual</font>     <font color="blue">property rights</font> of <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>From time to time, in the ordinary course     of business, we receive notices from <font color="blue">third parties</font> alleging <font color="blue">infringement</font> or     <font color="blue">misappropriation</font> of the patent, trademark and other <font color="blue"><font color="blue">intellectual</font> property</font>     rights of <font color="blue">third parties</font> by us or our consumers in <font color="blue">connection with</font> the use of     our products</td>
    </tr>
    <tr>
      <td>We may be unaware of <font color="blue"><font color="blue">intellectual</font> property</font> rights of others     that may cover some of our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>If someone claims that our products     infringe their <font color="blue"><font color="blue">intellectual</font> property</font> rights, whether or not such claims are     <font color="blue">meritorious</font>, any resulting <font color="blue">litigation</font> could be costly and time consuming and     would  divert the attention of our <font color="blue">management</font> and <font color="blue">personnel from</font> other     business  issues</td>
    </tr>
    <tr>
      <td>The  <font color="blue">complexity</font>  of the <font color="blue">technology</font> involved and the     <font color="blue">uncertainty</font> of <font color="blue"><font color="blue">intellectual</font> property</font> <font color="blue">litigation</font> increase these risks</td>
    </tr>
    <tr>
      <td><font color="blue">Claims     </font>of <font color="blue"><font color="blue">intellectual</font> property</font> <font color="blue">infringement</font> also might require us to <font color="blue">enter into</font>     costly royalty or license <font color="blue"><font color="blue">agreement</font>s</font> (if available on acceptable terms or at     all)</td>
    </tr>
    <tr>
      <td>We  also may be subject to <font color="blue">significant</font> damages or an injunction     preventing us from <font color="blue">manufacturing</font>, selling or using some or some aspect of     our products</td>
    </tr>
    <tr>
      <td>We may also need to redesign some of our products or processes     to avoid future <font color="blue">infringement</font> <font color="blue">liability</font></td>
    </tr>
    <tr>
      <td>Any of these adverse <font color="blue">consequences</font>     could have a material adverse effect on our business and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">manufacturing</font> <font color="blue">capacity</font> may not be adequate to meet the demands of our     business</td>
    </tr>
    <tr>
      <td>If our sales increase <font color="blue">substantially</font>, we may need to increase our production     <font color="blue">capacity</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">prolonged disruption</font> in the operation of our <font color="blue">manufacturing</font>     <font color="blue">facilities</font> or those of our third-party <font color="blue">manufacture</font>rs could <font color="blue">materially</font> harm     our  business</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that if we choose to scale-up our     <font color="blue">manufacturing</font> <font color="blue">operations</font>, we will be able to obtain <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font> in     a timely fashion, <font color="blue">which could</font> affect our ability to <font color="blue">meet product demand</font> or     result in <font color="blue">additional</font> costs</td>
    </tr>
    <tr>
      <td>We could experience losses due to <font color="blue">product <font color="blue">liability</font></font> claims, <font color="blue">product recalls</font>     or <font color="blue">correction</font>s</td>
    </tr>
    <tr>
      <td>We have in the past been, and continue to be, subject to <font color="blue">product <font color="blue">liability</font></font>     claims</td>
    </tr>
    <tr>
      <td>In <font color="blue">connection with</font> our spin-off from Allergan, we assumed the     defense of any <font color="blue">litigation</font> involving claims related to our business and     agreed to indemnify Allergan for all related losses, costs and expenses</td>
    </tr>
    <tr>
      <td>As     part of our risk <font color="blue">management</font> policy, we have obtained third-party product     <font color="blue"><font color="blue">liability</font> insurance coverage</font></td>
    </tr>
    <tr>
      <td>Product <font color="blue">liability</font> claims <font color="blue">against us may exceed</font>     the  <font color="blue">coverage limits</font> of our <font color="blue">insurance policies</font> or cause us to record a     self-insured  loss</td>
    </tr>
    <tr>
      <td>A <font color="blue">product <font color="blue">liability</font></font> claim in excess of applicable     <font color="blue">insurance could</font> have a material adverse effect on our business, financial     condition and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Even if any <font color="blue">product <font color="blue">liability</font></font> loss is     <font color="blue">covered by</font> an <font color="blue">insurance policy</font>, these policies have substantial <font color="blue">retentions</font>     or <font color="blue">deductibles</font> that provide that we will not receive <font color="blue">insurance proceeds</font>     until  the  losses  incurred  exceed the amount of those <font color="blue">retentions</font> or     <font color="blue">deductibles</font></td>
    </tr>
    <tr>
      <td>To the extent that any losses are below these <font color="blue">retentions</font> or     <font color="blue">deductibles</font>, we will be responsible for paying these losses</td>
    </tr>
    <tr>
      <td>The payment of     <font color="blue">retentions</font> or <font color="blue">deductibles</font> for a <font color="blue"><font color="blue">significant</font> amount</font> of claims could have a     material adverse effect on our business, <font color="blue">financial condition</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>18     ______________________________________________________________________         In addition, we are subject to medical device reporting <font color="blue">regulations</font> that     require us to report to the FDA or similar <font color="blue">governmental</font> <font color="blue">authorities</font> in other     countries if our products cause or contribute to a death or <font color="blue">serious injury</font>     or <font color="blue">malfunction</font> in a way that would be <font color="blue">reasonably likely</font> to contribute to     death  or <font color="blue">serious injury</font> if the <font color="blue">malfunction</font> were to recur</td>
    </tr>
    <tr>
      <td>The FDA and     similar <font color="blue">governmental</font> <font color="blue">authorities</font> in other countries have the authority to     require the recall of our products in the event of material <font color="blue">deficiencies</font> or     defects in design or <font color="blue">manufacturing</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">government mandated</font> or voluntary     <font color="blue">recall by us could</font> occur as a result of <font color="blue">manufacturing</font> errors or design     defects, including defects in labeling</td>
    </tr>
    <tr>
      <td>We have <font color="blue">undertaken voluntary recalls</font>     of our products in the past</td>
    </tr>
    <tr>
      <td>Any <font color="blue">product <font color="blue">liability</font></font> claim or <font color="blue">recall would divert managerial</font> and financial     resources and <font color="blue">could harm</font> our <font color="blue">reputation with customers</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you     that we will not have <font color="blue">product <font color="blue">liability</font></font> claims or recalls in the future or     that such claims or <font color="blue">recalls would</font> not have a material adverse effect on our     business</td>
    </tr>
    <tr>
      <td>If  we  fail to maintain our <font color="blue">relationships</font> with health care providers,     <font color="blue">customers may</font> not buy our products and our revenue and <font color="blue">profitability</font> may     decline</td>
    </tr>
    <tr>
      <td>We market our products to <font color="blue">numerous health care providers</font>, including eye care     professionals, hospitals, ambulatory surgical centers, corporate optometry     chains and group purchasing <font color="blue">organization</font>s</td>
    </tr>
    <tr>
      <td>We have developed and strive to     maintain close <font color="blue">relationships</font> with members of each of these groups who assist     in <font color="blue">product research</font> and <font color="blue">development</font> and <font color="blue">advise us on how</font> to satisfy the full     range of surgeon and patient needs</td>
    </tr>
    <tr>
      <td>We rely on these groups to recommend our     products to their patients and to other members of their <font color="blue">organization</font>s</td>
    </tr>
    <tr>
      <td>The     failure of our <font color="blue"><font color="blue">existing product</font>s</font> and any <font color="blue">new products</font> we <font color="blue">may introduce</font> to     retain the support of these <font color="blue">various groups could</font> have a material adverse     effect on our business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">generally</font> do not have long-term contracts with our customers</td>
    </tr>
    <tr>
      <td>We <font color="blue">generally</font> do not <font color="blue">enter into</font> long-term contracts with our customers</td>
    </tr>
    <tr>
      <td>As a     result, we are exposed to <font color="blue">volatility</font> in the market for our products and loss     of our customers</td>
    </tr>
    <tr>
      <td>As a result, we may not be able to maintain our level of     <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>If we are unable to market our <font color="blue">products on terms</font> we find     acceptable, our <font color="blue">financial condition</font> and results of <font color="blue">operations</font> could suffer     <font color="blue">materially</font></td>
    </tr>
    <tr>
      <td>Our business is subject to extensive <font color="blue">government regulation</font></td>
    </tr>
    <tr>
      <td>Our products and <font color="blue">operations</font> are subject to extensive regulation in the     <font color="blue"><font color="blue">United States</font> </font>by the FDA and various other federal and state <font color="blue">regulatory</font>     agencies, including with respect to <font color="blue">regulatory</font> clearance or approval of our     products, clinical and pre-clinical testing, product marketing, sales and     <font color="blue"><font color="blue">distribution</font>s</font>, adverse event reporting, <font color="blue">prohibitions</font> on fraud and abuse,     submission of false claims, kickbacks and rebates, and <font color="blue">relationships</font> with     physicians  and  other referral sources</td>
    </tr>
    <tr>
      <td>Additionally, in many foreign     countries  in  which we market our products, we are subject to similar     <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>Before a new medical device or new use of, or claim for, or <font color="blue">modification</font> to     an <font color="blue">existing product</font> can be marketed in the <font color="blue">United States</font>, a company must     first apply for and receive either 510(k) clearance, <font color="blue">premarket approval</font> or a     <font color="blue"><font color="blue">premarket approval</font> supplement from</font> the FDA, unless an <font color="blue">exemption applies</font></td>
    </tr>
    <tr>
      <td>Either  process can be expensive, lengthy and unpredictable</td>
    </tr>
    <tr>
      <td>Also, the     <font color="blue">identification</font> or increased frequency of safety or efficacy concerns could     result in product recall or withdrawal or revocation of our FDA clearance or     <font color="blue">premarket approval</font></td>
    </tr>
    <tr>
      <td><font color="blue">Compliance </font>with these <font color="blue">regulations</font> is expensive and     time-consuming</td>
    </tr>
    <tr>
      <td>We, our <font color="blue">subcontractors</font>, and <font color="blue">third party</font> <font color="blue">manufacture</font>rs are     subject to periodic and <font color="blue">unannounced inspections by</font> FDA and <font color="blue">governmental</font>     <font color="blue">authorities</font> to assess compliance</td>
    </tr>
    <tr>
      <td>If we fail to comply, the FDA and state or     other <font color="blue">regulatory</font> agencies have broad <font color="blue">enforcement</font> powers, including any of     the <font color="blue">following sanctions</font>:         •                  warning letters, fines, injunctions, consent decrees,     <font color="blue">civil penalties</font> and <font color="blue">exclusion from participation</font> in federal and state health     <font color="blue">care programs</font>;         •                  repair, <font color="blue">replacement</font>, recall or seizure of our products;         •                  operating <font color="blue">restrictions</font>, partial suspension or total     shutdown of production;         •                  refusing our requests for 510(k) clearance or premarket     approval of <font color="blue">new products</font>, new intended uses or <font color="blue">modification</font>s to existing     products;         •                  withdrawing 510(k) clearance or <font color="blue">premarket approval</font>s that     have <font color="blue">already been granted</font>; and         •                  <font color="blue">criminal prosecution</font> and penalties</td>
    </tr>
    <tr>
      <td>19     ______________________________________________________________________         Product sales, <font color="blue">introduction</font>s or <font color="blue">modification</font>s may be delayed or <font color="blue">canceled as</font>     a result of US or foreign <font color="blue">regulatory</font> processes, <font color="blue">which could</font> cause our     sales to decline</td>
    </tr>
    <tr>
      <td>Failure to obtain <font color="blue">regulatory</font> clearance or approvals of new     products or product <font color="blue">modification</font>s we develop, any <font color="blue">limitations</font> imposed by     <font color="blue">regulatory</font> agencies on new product uses or the costs of obtaining <font color="blue">regulatory</font>     clearance or <font color="blue">approvals could</font> have a material adverse effect on our business,     <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We, our <font color="blue">subcontractors</font>, and third-party <font color="blue">manufacture</font>rs are also subject to     similar  state  <font color="blue">requirements</font> and licenses</td>
    </tr>
    <tr>
      <td>We, our <font color="blue">subcontractors</font>, and     third-party <font color="blue">manufacture</font>rs must <font color="blue">comply with</font> extensive <font color="blue">recordkeeping</font> and     reporting <font color="blue">requirements</font> and must make available our <font color="blue"><font color="blue">manufacturing</font> <font color="blue">facilities</font></font>     and  records  for unannounced and periodic inspections by <font color="blue">governmental</font>     agencies, including FDA, state <font color="blue">authorities</font> and <font color="blue">comparable agencies</font> in other     countries</td>
    </tr>
    <tr>
      <td>Health <font color="blue">care initiatives</font> and other cost-containment pressures could cause us     to sell our <font color="blue">products at lower prices</font>, resulting in <font color="blue">less revenue</font> to us</td>
    </tr>
    <tr>
      <td>In     the <font color="blue">United States</font>, a <font color="blue">significant</font> percentage of the patients who receive our     <font color="blue">intraocular lenses</font> are <font color="blue">covered by</font> the federal Medicare program</td>
    </tr>
    <tr>
      <td>Changes in     coverage or coding policies or <font color="blue">reductions</font> <font color="blue">in Medicare </font><font color="blue">reimbursement rates</font>     and the <font color="blue">implementation</font> of other price controls could <font color="blue"><font color="blue">adversely</font> affect</font> our     revenues  and  financial  condition</td>
    </tr>
    <tr>
      <td>In addition, changes in existing     <font color="blue">regulatory</font> <font color="blue">requirements</font> or adoption of new <font color="blue">requirements</font> could hurt our     business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">clinical trial process</font> required to obtain <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font> is costly     and uncertain, and could result in delays in new product <font color="blue">introduction</font>s or     even an <font color="blue">inability</font> to release a product</td>
    </tr>
    <tr>
      <td>The <font color="blue">clinical trials</font> required to obtain <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font> for our products     are  complex  and expensive and their outcomes are uncertain</td>
    </tr>
    <tr>
      <td>We incur     substantial expense for, and devote <font color="blue">significant</font> time to, <font color="blue">clinical trials</font> but     cannot be certain that the <font color="blue">trials will ever</font> result in the <font color="blue">commercial sale</font> of     a product</td>
    </tr>
    <tr>
      <td>We may suffer <font color="blue">significant</font> setbacks in <font color="blue">clinical trials</font>, even after     earlier <font color="blue">clinical trials</font> showed promising results</td>
    </tr>
    <tr>
      <td>Any of our <font color="blue">products may</font>     produce  undesirable  side  effects  that could cause us or <font color="blue">regulatory</font>     <font color="blue">authorities</font>  to  interrupt, delay or halt <font color="blue">clinical trials</font> of a product     candidate</td>
    </tr>
    <tr>
      <td>We, the FDA, or another <font color="blue">regulatory</font> authority may suspend or     terminate  <font color="blue">clinical trials</font> at any time if they or we believe the trial     <font color="blue"><font color="blue">participant</font>s face</font> unacceptable <font color="blue">health risks</font></td>
    </tr>
    <tr>
      <td>Our business is subject to <font color="blue">environmental</font> <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>Our  <font color="blue">facilities</font> and <font color="blue">operations</font> are subject to federal, state and local     <font color="blue">environmental</font> and <font color="blue">occupational health</font> and safety <font color="blue">requirements</font> of the United     States and <font color="blue">foreign countries</font>, including those relating to discharges of     substances to the air, water and land, the handling, storage and disposal of     wastes and the cleanup of <font color="blue">properties affected by pollutants</font></td>
    </tr>
    <tr>
      <td>Failure to     maintain compliance with these <font color="blue">regulations</font> could have a material adverse     effect on our business or <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">facilities</font> we obtained in     <font color="blue">connection with</font> the <font color="blue">acquisition</font> of Pfizer’s <font color="blue">ophthalmic surgical</font> business and     in <font color="blue">connection with</font> our <font color="blue">acquisition</font> of VISX, Incorporated are also subject to     such <font color="blue">requirements</font> and risks</td>
    </tr>
    <tr>
      <td>In the future, federal, state or local <font color="blue">governments</font> in the <font color="blue"><font color="blue">United States</font> </font>or     <font color="blue">foreign countries</font> could enact new or more stringent laws or issue new or     more stringent <font color="blue">regulations</font> <font color="blue">concerning</font> <font color="blue">environmental</font> and <font color="blue">worker health</font> and     safety  matters that could affect our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Also, in the future,     <font color="blue">contamination may</font> be found to exist at our current or former <font color="blue">facilities</font> or     off-site locations where we have <font color="blue">sent wastes</font></td>
    </tr>
    <tr>
      <td>We could be held liable for     such newly discovered contamination <font color="blue">which could</font> have a material adverse     effect on our business or <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>In addition, changes in     <font color="blue">environmental</font>  and  <font color="blue">worker health</font> and safety <font color="blue">requirements</font> could have a     material adverse effect on our business or <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>If we fail to attract, hire and retain <font color="blue">qualified personnel</font>, we may not be     able to design, develop, market or sell our products or <font color="blue">successfully</font> manage     our business</td>
    </tr>
    <tr>
      <td>Our ability to attract new customers, retain <font color="blue">existing customers</font> and pursue     our <font color="blue">strategic <font color="blue">objectives</font> depends on</font> the <font color="blue">continued services</font> of our current     <font color="blue">management</font>, sales, product <font color="blue">development</font> and <font color="blue">technical personnel</font> and our     ability  to  identify,  attract,  train  and retain similar personnel</td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>for top <font color="blue">management</font> personnel is intense and we may not be able     to recruit and retain the personnel we need</td>
    </tr>
    <tr>
      <td>The loss of any one of our     <font color="blue">management</font> personnel, or our <font color="blue">inability</font> to identify, attract, retain and     integrate <font color="blue">additional</font> qualified <font color="blue">management</font> personnel, could make it <font color="blue">difficult</font>     for  us  to  manage our business <font color="blue">successfully</font> and pursue our strategic     <font color="blue">objectives</font></td>
    </tr>
    <tr>
      <td>Similarly, <font color="blue">competition</font> for skilled sales, product <font color="blue">development</font>     and <font color="blue">technical personnel</font> is intense and we may not be able to recruit and     retain the personnel we need</td>
    </tr>
    <tr>
      <td>The loss of services of a number of key sales,     product <font color="blue">development</font> and <font color="blue">technical personnel</font>, or our <font color="blue">inability</font> to hire new     <font color="blue">personnel with</font> the requisite skills, could restrict our ability to develop     <font color="blue">new products</font> or enhance <font color="blue"><font color="blue">existing product</font>s</font> in a <font color="blue">timely manner</font>, sell products     to our customers or manage our business <font color="blue"><font color="blue">effective</font>ly</font></td>
    </tr>
    <tr>
      <td>20     ______________________________________________________________________         We may not be able to hire or retain <font color="blue">qualified personnel</font> if we are unable to     offer <font color="blue">competitive</font> salaries and benefits</td>
    </tr>
    <tr>
      <td>If our stock does not perform well,     we may have to increase our salaries and benefits, which would increase our     expenses and reduce our <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We  may  be required to <font color="blue">satisfy certain <font color="blue">indemnification</font> <font color="blue">obligations</font></font> to     Allergan, and we may not be able to collect on <font color="blue">indemnification</font> rights from     Allergan</td>
    </tr>
    <tr>
      <td>Under  the  terms  of our <font color="blue">contribution</font> and <font color="blue">distribution</font> <font color="blue">agreement</font> with     Allergan, we and Allergan have <font color="blue">each agreed</font> to <font color="blue">indemnify each</font> other from and     after our spin-off with respect to the debt, <font color="blue">liabilities</font> and <font color="blue">obligations</font>     retained by our <font color="blue">respective companies</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">indemnification</font> <font color="blue">obligations</font>     could be <font color="blue">significant</font></td>
    </tr>
    <tr>
      <td>The ability to satisfy these <font color="blue">indemnities</font>, if called     upon to do so, <font color="blue">will depend upon</font> the <font color="blue">future financial strength</font> of each of our     <font color="blue">respective companies</font></td>
    </tr>
    <tr>
      <td>We cannot determine whether we will have to indemnify     Allergan for any substantial <font color="blue">obligations</font>, and we may not have <font color="blue">control over</font>     the settlement of certain claims and lawsuits that may require partial     <font color="blue">indemnification</font>  by us</td>
    </tr>
    <tr>
      <td>We also <font color="blue">cannot assure</font> you that, if Allergan is     required to <font color="blue">indemnify us</font> for any substantial <font color="blue">obligations</font>, Allergan will have     the ability to satisfy those <font color="blue">obligations</font></td>
    </tr>
    <tr>
      <td>We may be responsible for federal income tax <font color="blue">liabilities</font> that relate to the     <font color="blue">distribution</font> of our <font color="blue"><font color="blue">common stock</font> by</font> Allergan</td>
    </tr>
    <tr>
      <td>Allergan has received a <font color="blue">ruling from</font> the <font color="blue">Internal Revenue Service </font>to the     effect that the spin-off qualified as a tax-free transaction</td>
    </tr>
    <tr>
      <td>If <font color="blue">either us</font>     or Allergan breach representations to each other or to the Internal Revenue     Service, or if we or Allergan take or fail to take, as the case may be,     actions that result in the spin-off failing to meet the <font color="blue">requirements</font> of a     tax-free spin-off pursuant to Section 355 of the Internal Revenue Code, the     party in breach will indemnify the other party for any and all resulting     taxes</td>
    </tr>
    <tr>
      <td>If we were required to pay any of the <font color="blue">potential taxes described</font>     above, the <font color="blue">payment would</font> have a material adverse effect on our financial     position</td>
    </tr>
    <tr>
      <td>Recent changes in the <font color="blue">accounting treatment</font> of stock options are expected to     have a <font color="blue">negative impact on</font> our <font color="blue">financial statements</font> and could cause our stock     price to decline</td>
    </tr>
    <tr>
      <td><font color="blue">On <font color="blue">December </font></font>16, 2004, the Financial Accounting Standards Board (“FASB”)     issued FASB Statement Nodtta 123(R), Share-Based Payment, or FAS 123(R), which     includes <font color="blue">proposed rule</font> changes requiring companies to expense the <font color="blue">fair value</font>     of <font color="blue">employee stock options</font> and other forms of stock-based compensation</td>
    </tr>
    <tr>
      <td>Before 2006, we included the <font color="blue">fair value</font> of <font color="blue">employee stock options</font> on a pro     <font color="blue">forma basis</font> in the notes to our annual <font color="blue">financial statements</font> in <font color="blue">accordance</font>     with accounting principles <font color="blue">generally</font> accepted in the <font color="blue">United States</font>, but did     not  record a charge for <font color="blue">employee stock option expense</font> in the reported     financial  statements</td>
    </tr>
    <tr>
      <td>We are required to <font color="blue">comply with</font> FAS 123(R) as of     January 1, 2006 and, as a result, our reported earnings are expected to     decrease</td>
    </tr>
    <tr>
      <td>If laser vision <font color="blue">correction</font> is not <font color="blue">broadly accepted <font color="blue">by both doctors</font></font> and     patients, our business, <font color="blue">financial position</font> and results of <font color="blue">operations</font> would     be <font color="blue">materially</font> and <font color="blue">adversely</font> impacted</td>
    </tr>
    <tr>
      <td>Our business depends upon <font color="blue">broad market</font> <font color="blue">acceptance</font> of laser vision <font color="blue">correction</font>     <font color="blue">by both doctors</font> and patients in the <font color="blue"><font color="blue">United States</font> </font>and key <font color="blue">international</font>     markets</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">profitability</font>  and  <font color="blue">growth will</font> be <font color="blue">largely <font color="blue">dependent on</font></font>     <font color="blue">increasing levels</font> of market <font color="blue">acceptance</font> and procedure growth, <font color="blue">especially</font> with     regard to our higher-priced CustomVue™ procedure</td>
    </tr>
    <tr>
      <td><font color="blue">Potential </font><font color="blue">complications</font>     and  side  effects  of laser vision <font color="blue">correction</font> include: post-operative     discomfort, corneal haze (an increase in the <font color="blue">light scattering properties</font> of     the cornea) during healing, glare/halos (undesirable visual sensations     produced by bright lights), decreases in contrast sensitivity, temporary     increases in <font color="blue">intraocular pressure</font> in reaction to <font color="blue">procedure medication</font>,     modest  <font color="blue">fluctuations</font> in <font color="blue">refractive capabilities during healing</font>, modest     decrease  in  best  corrected  vision (ie, with corrective eyewear),     <font color="blue">unintended over</font>- or under-<font color="blue">correction</font>s, regression of effect, disorders of     corneal healing, corneal scars, corneal ulcers, and <font color="blue">induced astigmatism</font>     (which may result in blurred or double vision and/or shadow images)</td>
    </tr>
    <tr>
      <td><font color="blue">Some     </font><font color="blue"><font color="blue">consumers may</font> choose</font> not to undergo laser vision <font color="blue">correction</font> because of these     <font color="blue">complications</font> or more general concerns relating to its safety and efficacy     or a resistance to surgery in general</td>
    </tr>
    <tr>
      <td>Alternatively, some <font color="blue">consumers may</font>     elect to delay undergoing laser vision <font color="blue">correction</font> surgery because they     believe improved <font color="blue">technology</font> or methods of <font color="blue">treatment will</font> be available in the     near  future</td>
    </tr>
    <tr>
      <td>Should  either  the <font color="blue">ophthalmic community</font> or the general     population turn away from laser vision <font color="blue">correction</font> as an <font color="blue">alternative</font> to     <font color="blue">existing methods</font> of <font color="blue">treating refractive vision disorders</font>, or if future     <font color="blue">technologies</font> replaced laser vision <font color="blue">correction</font>, these <font color="blue">development</font>s could     delay or prevent market <font color="blue">acceptance</font> of laser vision <font color="blue">correction</font>, <font color="blue">which could</font>     have a material adverse effect on our business, <font color="blue">financial position</font> and     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">possibility</font> of long-term side effects and <font color="blue">adverse publicity</font> regarding     laser <font color="blue">correction</font> surgery could seriously harm our business</td>
    </tr>
    <tr>
      <td>Laser vision <font color="blue">correction</font> is a <font color="blue">relatively new procedure</font></td>
    </tr>
    <tr>
      <td>Consequently, there     is no long-term follow-up data beyond ten years that might reveal <font color="blue">additional</font>     <font color="blue">complications</font> or unknown side effects</td>
    </tr>
    <tr>
      <td>Any future reported side effects,     other adverse events or                                           21     ______________________________________________________________________         <font color="blue">unfavorable publicity involving patient outcomes</font> resulting from the use of     laser vision <font color="blue">correction</font> systems <font color="blue">manufacture</font>d by us or any <font color="blue">participant</font> in the     laser vision <font color="blue">correction</font> market, may have a material adverse effect on our     business, <font color="blue">financial position</font>, and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>General <font color="blue"><font color="blue">economic <font color="blue">conditions</font></font> could</font> have a <font color="blue">negative impact on</font> our business,     <font color="blue">financial position</font>, and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Because  </font>laser  vision <font color="blue">correction</font> is not subject to <font color="blue">reimbursement from</font>     third-party payors such as insurance companies or <font color="blue">government programs</font>, the     cost of laser vision <font color="blue">correction</font> is <font color="blue">typically borne by <font color="blue">individuals</font> directly</font></td>
    </tr>
    <tr>
      <td>Accordingly, weak or <font color="blue">uncertain <font color="blue">economic <font color="blue">conditions</font></font> may</font> cause <font color="blue">individuals</font> to     be <font color="blue">less willing</font> to incur the <font color="blue">procedure cost <font color="blue">associated with</font> laser vision</font>     <font color="blue">correction</font> as was <font color="blue">evidenced by</font> VISX’s decline in revenues from 2002 compared     to 2001 and from 2001 compared to 2000</td>
    </tr>
    <tr>
      <td>A decline in <font color="blue">economic <font color="blue">conditions</font></font>,     <font color="blue">especially</font> in the <font color="blue">United States</font>, could result in a decline in the number of     laser vision <font color="blue">correction</font> procedures performed and could have a material     adverse  effect  on  our  business, <font color="blue">financial position</font>, and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>While we devote <font color="blue">significant</font> resources to research and <font color="blue">development</font>, our     research  and  <font color="blue">development</font>  may  not lead to <font color="blue">new products</font> that achieve     <font color="blue">commercial success</font></td>
    </tr>
    <tr>
      <td>Our research and <font color="blue">development</font> process is expensive, prolonged, and entails     considerable <font color="blue">uncertainty</font></td>
    </tr>
    <tr>
      <td>Because of the <font color="blue">complexities</font> and <font color="blue">uncertainties</font>     associated  with  <font color="blue">ophthalmic research</font> and <font color="blue">development</font>, products we are     currently developing may not complete the <font color="blue">development</font> process or obtain the     <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font> required to market <font color="blue">such products</font> <font color="blue">successfully</font></td>
    </tr>
    <tr>
      <td>The     products  currently in our <font color="blue">development</font> pipeline may not be <font color="blue">approved by</font>     <font color="blue">regulatory</font> entities and may not be <font color="blue">commercially</font> successful, and our current     and  planned <font color="blue">products could</font> be <font color="blue">surpassed by</font> more <font color="blue">effective</font> or advanced     products</td>
    </tr>
    <tr>
      <td>Any <font color="blue">failure by <font color="blue">third party</font> financing entities</font> to satisfy their <font color="blue">obligations</font>     to <font color="blue">us would negatively impact</font> our <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">relationships</font> with <font color="blue">third party</font> financing entities that purchase our     products directly and subsequently lease and/or sell these products to     end-user customers, or <font color="blue">provide financing directly</font> to customers who purchase     products  <font color="blue">directly from us</font></td>
    </tr>
    <tr>
      <td>Should any <font color="blue">third party</font> financing entity or     entities fail or refuse to pay us in a <font color="blue">timely manner</font> or at all, it could     <font color="blue">negatively affect</font> our <font color="blue"><font color="blue">cash flow</font>s</font> and could have a material adverse effect on     our business, <font color="blue">financial position</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If any of our employees, consultants or <font color="blue">others breach</font> their <font color="blue">proprietary</font>     information <font color="blue"><font color="blue">agreement</font>s</font>, our <font color="blue">competitive</font> position could be harmed</td>
    </tr>
    <tr>
      <td>We  protect  our  <font color="blue">proprietary</font> <font color="blue">technology</font>, in part, through <font color="blue">proprietary</font>     information and inventions <font color="blue"><font color="blue">agreement</font>s</font> with employees, consultants and other     parties</td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">agreement</font>s</font> with employees and consultants <font color="blue">generally</font> contain     standard provisions requiring those <font color="blue">individuals</font> to assign to us, without     <font color="blue">additional</font> consideration, inventions conceived or reduced to <font color="blue">practice by</font>     <font color="blue">them while employed</font> or retained by us, subject to <font color="blue">customary <font color="blue">exceptions</font></font></td>
    </tr>
    <tr>
      <td>If     any of our employees, consultants or <font color="blue">others breach</font> these <font color="blue"><font color="blue">agreement</font>s</font> our     <font color="blue">competitors</font> may learn of our <font color="blue">trade secrets</font></td>
    </tr>
    <tr>
      <td>Risks Relating to Our Indebtedness and Our Common Stock         We have a <font color="blue"><font color="blue">significant</font> amount</font> of debt</td>
    </tr>
    <tr>
      <td>Our substantial <font color="blue"><font color="blue">indebtedness</font> could</font>     <font color="blue"><font color="blue">adversely</font> affect</font> our business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font>     and our ability to meet our payment <font color="blue">obligations</font> under our debt</td>
    </tr>
    <tr>
      <td>We  have  a  <font color="blue">significant</font>  amount  of debt and substantial <font color="blue">debt service</font>     <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td><font color="blue">As of <font color="blue">December </font></font>31, 2005, we had approximately dlra560 million of     outstanding  debt</td>
    </tr>
    <tr>
      <td><font color="blue">Approximately </font>dlra18dtta7 million of our revolving credit     <font color="blue">facility</font> was reserved to <font color="blue">support letters</font> of credit issued on our behalf and     approximately dlra231dtta3 million, exclusive of letters of credit, was available     for <font color="blue">future borrowings</font></td>
    </tr>
    <tr>
      <td>This  level  of <font color="blue">debt could</font> have <font color="blue">significant</font> <font color="blue">consequences</font> on our future     <font color="blue">operations</font>, including:         •                                          making it more <font color="blue">difficult</font> for us     to meet our payment and other <font color="blue">obligations</font> under our <font color="blue">outstanding debt</font>;         •                                          resulting in an event of default     if we fail to <font color="blue">comply with</font> the financial and other <font color="blue">restrictive covenants</font>     contained in our debt <font color="blue"><font color="blue">agreement</font>s</font>, which event of <font color="blue">default could</font> result in all     of our <font color="blue">debt becoming <font color="blue">immediately due</font></font> and payable;         •                                          reducing the <font color="blue">availability</font> of our     <font color="blue">cash flow</font> to fund working capital, capital <font color="blue">expenditures</font>, <font color="blue">acquisition</font>s and     other  general  <font color="blue">corporate purposes</font>, and limiting our ability to obtain     <font color="blue">additional</font> financing for these purposes;                                           22     ______________________________________________________________________         •                                          <font color="blue">subjecting us</font> to the risk of     <font color="blue">increased sensitivity</font> to <font color="blue">interest rate increases on</font> our <font color="blue"><font color="blue">indebtedness</font> with</font>     variable  <font color="blue">interest rates</font>, including <font color="blue">borrowings under</font> our senior credit     <font color="blue">facility</font>;         •                                          limiting our <font color="blue">flexibility</font> in     planning for, or reacting to, and increasing our <font color="blue">vulnerability</font> to, changes     in our business, the industry in which we operate and the <font color="blue">general economy</font>;     and         •                                          <font color="blue">placing us at</font> a <font color="blue">competitive</font>     <font color="blue">disadvantage compared</font> to our <font color="blue">competitors</font> that have less debt or are less     leveraged</td>
    </tr>
    <tr>
      <td>Any  of  the  above-listed factors could have an adverse effect on our     business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font> and our ability to     meet our payment <font color="blue">obligations</font> under the notes and our other debt</td>
    </tr>
    <tr>
      <td>To service our <font color="blue">indebtedness</font>, we will require a <font color="blue"><font color="blue">significant</font> amount</font> of cash</td>
    </tr>
    <tr>
      <td>Our  ability  to generate <font color="blue">cash flow</font> depends on many <font color="blue">factors beyond</font> our     control</td>
    </tr>
    <tr>
      <td>Our ability to meet our payment and other <font color="blue">obligations</font> under our <font color="blue">debt depends</font>     on our ability to generate <font color="blue">significant</font> <font color="blue">cash flow</font> in the future</td>
    </tr>
    <tr>
      <td>This, to     some  extent,  is subject to general economic, financial, <font color="blue">competitive</font>,     <font color="blue">legislative</font> and <font color="blue">regulatory</font> factors as well as other factors that are beyond     our control</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> holders that our business <font color="blue">will generate cash</font>     flow from <font color="blue">operations</font>, or that <font color="blue">future borrowings</font> will be available to us     under our senior credit <font color="blue">facility</font> or otherwise, in an <font color="blue">amount sufficient</font> to     <font color="blue">enable us</font> to meet our payment <font color="blue">obligations</font> under our debt and to fund other     liquidity needs</td>
    </tr>
    <tr>
      <td>We made an <font color="blue">irrevocable election</font> to satisfy in cash our     <font color="blue"><font color="blue">conversion</font> obligation</font> with respect to the <font color="blue">principal amount</font> of any of our     2dtta50prca convertible senior subordinated notes due 2024 (the “Existing 2dtta50prca     Convertible Notes”) converted after <font color="blue">December </font>15, 2004, with any remaining     amount of the <font color="blue"><font color="blue">conversion</font> obligation</font> to be satisfied in shares of our common     stock, in each case, calculated as set forth in the <font color="blue">indenture governing</font> the     <font color="blue">Existing  </font>2dtta50prca  Convertible  Notes</td>
    </tr>
    <tr>
      <td>In addition, because we made this     election,  the  indenture  provides  that  we <font color="blue">must satisfy</font> in cash our     <font color="blue">obligations</font> to repurchase any Existing 2dtta50prca <font color="blue">Convertible Notes </font>that holders     put to us on January 15, 2010, July 15, 2014 and July 15, 2019</td>
    </tr>
    <tr>
      <td><font color="blue">If the Existing </font>2dtta50prca <font color="blue">Convertible Notes </font><font color="blue">become convertible pursuant</font> to their     terms and the <font color="blue">holders elect</font> to convert or if <font color="blue">holders elect</font> to put their     notes to us on the <font color="blue">specified repurchase dates</font>, we may not have sufficient     cash to satisfy our <font color="blue">obligations</font></td>
    </tr>
    <tr>
      <td>In addition, our 1dtta375prca convertible senior     subordinated notes due 2025 contain similar provisions, we may be unable to     repurchase  the notes for cash when required by the holders, including     following a <font color="blue">fundamental</font> change, or to pay the portion of the <font color="blue">conversion</font>     value upon <font color="blue">conversion</font> of any notes by the holders</td>
    </tr>
    <tr>
      <td>Our repurchase of any     such notes may be <font color="blue">prohibited by</font> our other debt instruments, <font color="blue">which could</font>     cause <font color="blue">defaults</font> and cross-<font color="blue">defaults</font> under our other debt <font color="blue"><font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td>If we are     not able to generate sufficient <font color="blue">cash flow</font> to service our debt <font color="blue">obligations</font>,     we may need to refinance or <font color="blue">restructure</font> our, sell assets, reduce or delay     capital <font color="blue">investment</font>s, or seek to raise <font color="blue">additional</font> capital</td>
    </tr>
    <tr>
      <td>If we are unable     to implement one or more of these <font color="blue">alternative</font>s, we may not be able to meet     our payment <font color="blue">obligations</font> under the notes and our other debt</td>
    </tr>
    <tr>
      <td>A <font color="blue"><font color="blue">significant</font> amount</font> of our debt <font color="blue"><font color="blue">agreement</font>s</font> contain covenant <font color="blue">restrictions</font>     that may limit our ability to operate our business</td>
    </tr>
    <tr>
      <td>The  <font color="blue"><font color="blue">agreement</font>s</font>  governing our senior credit <font color="blue">facility</font> contain covenant     <font color="blue">restrictions</font> that limit our ability to operate our business, including     <font color="blue">restrictions</font> on our ability to:         •                                          incur <font color="blue">additional</font> debt or issue     <font color="blue">guarantees</font>;         •                                          create liens;         •                                          make certain <font color="blue">investment</font>s;         •                                          <font color="blue">enter into</font> <font color="blue">transactions</font> with our     <font color="blue">affiliates</font>;         •                                          <font color="blue">sell certain assets</font>;         •                                          <font color="blue">redeem capital stock</font> or make     other <font color="blue">restricted payments</font>;         •                                          declare or <font color="blue">pay dividends</font> or make     other <font color="blue"><font color="blue">distribution</font>s</font> to <font color="blue">stockholders</font>; and         •                                          consolidate, merge or transfer     all or <font color="blue">substantially</font> all of our assets and the assets of our <font color="blue">subsidiaries</font> on     a <font color="blue">consolidated</font> basis</td>
    </tr>
    <tr>
      <td>23     ______________________________________________________________________         Our senior credit <font color="blue">facility</font> requires us to maintain <font color="blue">specific leverage</font>, fixed     <font color="blue">charge coverage</font> and <font color="blue">interest coverage ratios</font></td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">comply with</font>     these  covenants is <font color="blue">dependent on</font> our future performance, which will be     subject to many factors, some of which are beyond our control, including     prevailing <font color="blue">economic <font color="blue">conditions</font></font></td>
    </tr>
    <tr>
      <td>Our failure to <font color="blue">comply with</font> these <font color="blue">obligations</font>     would <font color="blue">prevent us</font> from borrowing <font color="blue">additional</font> money under the <font color="blue">facility</font> and     could result in a <font color="blue">default under</font> it</td>
    </tr>
    <tr>
      <td>If a default occurs under any of our     senior  <font color="blue">indebtedness</font>,  the <font color="blue">relevant lenders could elect</font> to declare the     <font color="blue">indebtedness</font>,  together  with  accrued  interest and other fees, to be     <font color="blue">immediately due</font> and payable and proceed against <font color="blue">substantially</font> all of our     assets, which will serve as collateral securing the <font color="blue">indebtedness</font></td>
    </tr>
    <tr>
      <td>Moreover,     if  the <font color="blue">lenders under</font> a <font color="blue">facility</font> or other <font color="blue">agreement</font> in default were to     <font color="blue">accelerate</font> the <font color="blue">indebtedness</font> outstanding under that <font color="blue">facility</font>, it could result     in  a  default  under  other  <font color="blue">indebtedness</font></td>
    </tr>
    <tr>
      <td>If all or any part of our     <font color="blue">indebtedness</font> were to be <font color="blue">accelerate</font>d, we may not have or be able to obtain     <font color="blue">sufficient funds</font> to repay it</td>
    </tr>
    <tr>
      <td>In addition, we may incur other <font color="blue">indebtedness</font>     in the future that <font color="blue">may contain financial</font> or other covenants that are more     <font color="blue">restrictive than</font> those contained in our <font color="blue">current indentures</font></td>
    </tr>
    <tr>
      <td>As  a  result of these covenants, our ability to respond to changes in     business and <font color="blue">economic <font color="blue">conditions</font></font> and to obtain <font color="blue">additional</font> financing, if     needed,  may be <font color="blue">significant</font>ly restricted, and we may be <font color="blue">prevented from</font>     engaging  in <font color="blue">transactions</font> that <font color="blue">might otherwise</font> be <font color="blue">beneficial</font> to us</td>
    </tr>
    <tr>
      <td>In     addition, our failure to <font color="blue">comply with</font> these <font color="blue">covenants could</font> result in a     <font color="blue">default under</font> our debt, <font color="blue">which could</font> permit the holders to <font color="blue">accelerate</font> such     debt</td>
    </tr>
    <tr>
      <td>If any of our debt is <font color="blue">accelerate</font>d, we may not have <font color="blue">sufficient funds</font>     available to <font color="blue">repay such debt</font></td>
    </tr>
    <tr>
      <td>Despite our and our <font color="blue">subsidiaries</font>’ <font color="blue">current levels</font> of <font color="blue">indebtedness</font>, we may     incur <font color="blue">substantially</font> more debt, <font color="blue">which could</font> further exacerbate the risks     <font color="blue">associated with</font> our substantial <font color="blue">indebtedness</font></td>
    </tr>
    <tr>
      <td><font color="blue">Although  </font>certain  of  our debt <font color="blue"><font color="blue">agreement</font>s</font> contain <font color="blue">restrictions</font> on the     incurrence of <font color="blue">additional</font> <font color="blue">indebtedness</font>, these <font color="blue">restrictions</font> are subject to a     number of <font color="blue">qualifications</font> and <font color="blue">exceptions</font>, and the <font color="blue">indebtedness</font> incurred in     compliance  with  these <font color="blue">restrictions</font> could be substantial</td>
    </tr>
    <tr>
      <td>Also, these     <font color="blue">restrictions</font>  do not <font color="blue">prevent us</font> from incurring <font color="blue">obligations</font> that do not     constitute “<font color="blue">indebtedness</font>” as defined in the relevant <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>If new debt     is added to our <font color="blue">current debt levels</font>, the related risks that we now face     <font color="blue">could intensify</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">stock price may fluctuate as</font> a result of a variety of factors, many of     which are beyond our control</td>
    </tr>
    <tr>
      <td>These factors include:         •                                          <font color="blue">quarterly variations</font> in our     operating results;         •                                          operating results that vary from     the <font color="blue">expectations</font> of <font color="blue">management</font>, securities analysts and investors;         •                                          changes in <font color="blue">expectations</font> as to our     <font color="blue">future financial performance</font>;         •                                          <font color="blue">announcements</font> of <font color="blue">innovations</font>, new     products, strategic <font color="blue">development</font>s, <font color="blue">significant</font> contracts, <font color="blue">acquisition</font>s and     other material <font color="blue">events by us</font> or our <font color="blue">competitors</font>;         •                                          the operating and securities     <font color="blue">price performance</font> of other companies that investors believe are comparable     to us;         •                                          <font color="blue">future sales</font> of our equity or     equity-related securities;         •                                          changes in general <font color="blue">conditions</font> in     our industry and in the economy, the <font color="blue">financial markets</font> and the domestic or     <font color="blue">international</font> political situation;         •                                           <font color="blue">development</font>s  or  disputes     (including lawsuits) <font color="blue">concerning</font> <font color="blue"><font color="blue">proprietary</font> rights</font>;         •                                          <font color="blue">departures</font> of <font color="blue">key personnel</font>; and         •                                          <font color="blue">regulatory</font> considerations</td>
    </tr>
    <tr>
      <td>In addition, in <font color="blue">recent years</font>, the <font color="blue">stock market</font> in general has experienced     <font color="blue">extreme price</font> and volume <font color="blue">fluctuations</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">volatility</font> has had a <font color="blue">significant</font>     effect  on the <font color="blue">market price</font> of <font color="blue">securities issued by</font> many companies for     <font color="blue">reasons often unrelated</font> to their operating performance</td>
    </tr>
    <tr>
      <td>These <font color="blue">broad market</font>     <font color="blue">fluctuations</font>  may  <font color="blue"><font color="blue">adversely</font> affect</font> our stock price, regardless of our     operating results</td>
    </tr>
    <tr>
      <td>24     ______________________________________________________________________         Our  stockholder  rights  plan,  amended  and  <font color="blue">restated <font color="blue">certificate</font></font> of     <font color="blue">incorporation</font> and bylaws, as well as provisions of <font color="blue">Delaware </font>law, could make     it <font color="blue">difficult</font> for a <font color="blue">third party</font> to acquire our company</td>
    </tr>
    <tr>
      <td>We have a <font color="blue">stockholder rights</font> plan that may have the effect of <font color="blue">discouraging</font>     <font color="blue">unsolicited takeover proposals</font></td>
    </tr>
    <tr>
      <td>The rights issued under the stockholder     rights plan would cause substantial dilution to a person or group that     attempts to acquire us on terms not approved in <font color="blue">advance by</font> our board of     <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">Delaware </font><font color="blue">corporate law</font> and our amended and restated     <font color="blue">certificate</font> of <font color="blue">incorporation</font> and <font color="blue">bylaws contain provisions</font> that <font color="blue">could delay</font>,     deter or prevent a change in control of our company or our <font color="blue">management</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">provisions could also discourage proxy contests</font> and make it more <font color="blue">difficult</font>     for our <font color="blue">stockholders</font> to elect <font color="blue">directors</font> and take other <font color="blue">corporate actions</font>     without the <font color="blue">concurrence</font> of our <font color="blue">management</font> or board of <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>provisions:         •                                          authorize our board of <font color="blue">directors</font>     to issue “blank check” <font color="blue">preferred stock</font>, which is <font color="blue">preferred stock</font> that can be     created and issued by our board of <font color="blue">directors</font>, without stockholder approval,     <font color="blue">with rights senior</font> to those of <font color="blue">common stock</font>;         •                                          provide for a <font color="blue">staggered board</font> of     <font color="blue">directors</font> and three-year terms for <font color="blue">directors</font>, so that no more than one-third     of our <font color="blue">directors</font> could be <font color="blue">replaced at</font> any <font color="blue">annual meeting</font>;         •                                          provide that <font color="blue">directors</font> may be     <font color="blue">removed only</font> for cause;         •                                          provide that <font color="blue">stockholder action</font>     may  be  <font color="blue">taken only at</font> a special or <font color="blue">regular meeting</font> and not by written     consent;         •                                          provide for super-majority voting     <font color="blue">requirements</font> for some provisions of our charter; and         •                                           establish  advance  notice     <font color="blue">requirements</font>  for  <font color="blue">submitting nominations</font> for election to the board of     <font color="blue">directors</font> and for <font color="blue">proposing matters</font> that can be acted upon by <font color="blue">stockholders</font>     at a meeting</td>
    </tr>
    <tr>
      <td>We are also subject to anti-takeover provisions under <font color="blue">Delaware </font>law, which     <font color="blue">could also delay</font> or prevent a change of control</td>
    </tr>
    <tr>
      <td>Together, these provisions     of  our  amended and <font color="blue">restated <font color="blue">certificate</font></font> of <font color="blue">incorporation</font> and bylaws,     <font color="blue">Delaware </font>law and our <font color="blue">stockholder rights</font> plan may discourage <font color="blue">transactions</font>     that <font color="blue">otherwise could provide</font> for the payment of a <font color="blue">premium over prevailing</font>     <font color="blue">market price</font>s of our <font color="blue">common stock</font> and, possibly, the notes, and also could     limit the price that investors are willing to pay in the future for shares     of our <font color="blue">common stock</font> and the notes</td>
    </tr>
  </tbody>
</table>